Immune checkpoint inhibitors continuation beyond progression as second-line treatment for extensive-stage small-cell lung cancer: a real-world, multicenter analysis

BackgroundOptimal management of extensive-stage small-cell lung cancer (ES-SCLC) following progression on first-line (1L) chemoimmunotherapy remains undefined. This study aimed to evaluate the efficacy of immune checkpoint inhibitors (ICIs) continuation in a second-line (2L) treatment setting.Method...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Jiao Zhang, Rui Zi, Hai-xia Zhang, Ye Lv, Lu-jun Zhao, Yan Wang
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Frontiers Media S.A. 2025-11-01
Цуврал:	Frontiers in Immunology
Нөхцлүүд:	extensive-stage small cell lung cancer chemoimmunotherapy second-line therapy survival prognosis
Онлайн хандалт:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1666373/full
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!